Joost de Bruijn
Founder bei KUROS BIOSCIENCES AG
Vermögen: 10 Mio $ am 31.03.2024
Aktive Positionen von Joost de Bruijn
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
KUROS BIOSCIENCES AG | Director/Board Member | 14.06.2018 | - |
Chief Tech/Sci/R&D Officer | 12.10.2023 | - | |
Founder | - | - | |
Chief Executive Officer | 04.12.2017 | 12.10.2023 | |
University of London | Corporate Officer/Principal | 18.03.2014 | - |
Chairman | - | 18.03.2014 | |
Queen Mary University of London | Corporate Officer/Principal | 01.01.2004 | - |
Karriereverlauf von Joost de Bruijn
Ehemalige bekannte Positionen von Joost de Bruijn
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
University of Twente | Corporate Officer/Principal | 01.01.2011 | 01.01.2019 |
Scinus Cell Expansion BV | Founder | - | - |
IsoTis SA
IsoTis SA BiotechnologyHealth Technology IsoTis SA develops biomedical products. Its product include proprietary natural and synthetic bone graft substitutes and other related medical devices. These devices are used to enhance the repair and regeneration of bone in spinal and trauma surgery, joint replacements and dental applications. IsoTis' products are primarily used spinal fusion, trauma, joint revision, bone void filling and iliac crest backfills procedures. The company is headquartered in Lausanne, Switzerland. | Chief Tech/Sci/R&D Officer | - | - |
Xpand Biotechnology BV
Xpand Biotechnology BV BiotechnologyHealth Technology Xpand Biotechnology BV develops innovative technologies in the area of cell cultivation and regenerative medicine. Its bioreactor system enables clinical scale cell cultivation in a controlled environment and provides a cost effective alternative to 2 dimensional cell growth in tissue culture flasks or cell stacks. The company was founded by Joost D. de Bruijin and Frank-Jan van der Velden in 2004 and is headquartered in Bilthoven, the Netherlands. | Chief Executive Officer | 01.01.2005 | - |
Founder | 01.01.2005 | - | |
President | 01.01.2005 | - | |
Progentix Orthobiology BV
Progentix Orthobiology BV Medical SpecialtiesHealth Technology Progentix Orthobiology BV develops CuriOs (TM), a unique suite of osteoconductive material products for clinical application in bone regenerative surgery. The company was founded by Joost Dick de Bruijn and Clemens A. van Blitterswijk in 2007 and is headquartered in Bilthoven, the Netherlands. | Chief Executive Officer | 01.01.2007 | - |
Founder | 15.04.2010 | - |
Ausbildung von Joost de Bruijn
University of Leiden | Doctorate Degree |
Statistik
International
Niederlande | 6 |
Schweiz | 3 |
Vereinigtes Königreich | 3 |
Operativ
Founder | 4 |
Chief Executive Officer | 3 |
Corporate Officer/Principal | 3 |
Sektoral
Health Technology | 5 |
Consumer Services | 5 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
KUROS BIOSCIENCES AG | Health Technology |
Private Unternehmen | 4 |
---|---|
Progentix Orthobiology BV
Progentix Orthobiology BV Medical SpecialtiesHealth Technology Progentix Orthobiology BV develops CuriOs (TM), a unique suite of osteoconductive material products for clinical application in bone regenerative surgery. The company was founded by Joost Dick de Bruijn and Clemens A. van Blitterswijk in 2007 and is headquartered in Bilthoven, the Netherlands. | Health Technology |
IsoTis SA
IsoTis SA BiotechnologyHealth Technology IsoTis SA develops biomedical products. Its product include proprietary natural and synthetic bone graft substitutes and other related medical devices. These devices are used to enhance the repair and regeneration of bone in spinal and trauma surgery, joint replacements and dental applications. IsoTis' products are primarily used spinal fusion, trauma, joint revision, bone void filling and iliac crest backfills procedures. The company is headquartered in Lausanne, Switzerland. | Health Technology |
Xpand Biotechnology BV
Xpand Biotechnology BV BiotechnologyHealth Technology Xpand Biotechnology BV develops innovative technologies in the area of cell cultivation and regenerative medicine. Its bioreactor system enables clinical scale cell cultivation in a controlled environment and provides a cost effective alternative to 2 dimensional cell growth in tissue culture flasks or cell stacks. The company was founded by Joost D. de Bruijin and Frank-Jan van der Velden in 2004 and is headquartered in Bilthoven, the Netherlands. | Health Technology |
Scinus Cell Expansion BV |
- Börse
- Insiders
- Joost de Bruijn
- Erfahrung